Organogenesis Holdings Inc
NASDAQ:ORGO
Organogenesis Holdings Inc
Revenue
Organogenesis Holdings Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Organogenesis Holdings Inc
NASDAQ:ORGO
|
Revenue
$435.4m
|
CAGR 3-Years
5%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$29.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$10.2B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
26%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
15%
|
CAGR 10-Years
19%
|
Organogenesis Holdings Inc
Revenue Breakdown
Breakdown by Geography
Organogenesis Holdings Inc
Breakdown by Segments
Organogenesis Holdings Inc
Total Revenue:
433.1m
USD
|
Advanced Wound Care:
405.5m
USD
|
Surgical And Sports Medicine:
27.6m
USD
|
See Also
What is Organogenesis Holdings Inc's Revenue?
Revenue
435.4m
USD
Based on the financial report for Mar 31, 2024, Organogenesis Holdings Inc's Revenue amounts to 435.4m USD.
What is Organogenesis Holdings Inc's Revenue growth rate?
Revenue CAGR 5Y
12%
Over the last year, the Revenue growth was -6%. The average annual Revenue growth rates for Organogenesis Holdings Inc have been 5% over the past three years , 12% over the past five years .